Nanthealth LLC (NYSE:NH) saw unusually-high trading volume on Thursday . Approximately 196,637 shares traded hands during mid-day trading, an increase of 129% from the previous session’s volume of 85,927 shares.The stock last traded at $12.63 and had previously closed at $12.44.

NH has been the topic of several analyst reports. FBR & Co initiated coverage on Nanthealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $18.00 target price on the stock. Cowen and Company initiated coverage on Nanthealth in a report on Monday, June 27th. They issued an “outperform” rating and a $19.00 price target for the company. First Analysis initiated coverage on Nanthealth in a report on Monday, June 27th. They issued an “overweight” rating and a $18.00 price target for the company. Canaccord Genuity initiated coverage on Nanthealth in a report on Monday, June 27th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Jefferies Group initiated coverage on Nanthealth in a report on Monday, June 27th. They issued a “buy” rating for the company. Five investment analysts have rated the stock with a buy rating, Nanthealth has a consensus rating of “Buy” and an average target price of $18.00.

The stock’s market capitalization is $1.53 billion. The stock has a 50-day moving average of $11.56 and a 200 day moving average of $12.37.

Nanthealth (NYSE:NH) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.26. The firm had revenue of $31.50 million for the quarter, compared to analyst estimates of $23.55 million. The business’s quarterly revenue was up 166.9% compared to the same quarter last year. Equities analysts predict that Nanthealth LLC will post ($0.59) EPS for the current year.

In related news, major shareholder Healthcare Solution Allscripts bought 714,286 shares of the stock in a transaction dated Tuesday, June 7th. The stock was bought at an average cost of $14.00 per share, with a total value of $10,000,004.00. Following the completion of the acquisition, the insider now owns 15,000,000 shares of the company’s stock, valued at $210,000,000. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Patrick Soon-Shiong bought 357,143 shares of the stock in a transaction dated Tuesday, June 7th. The shares were bought at an average cost of $14.00 per share, with a total value of $5,000,002.00. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.